Vendor Intelligence Report: Tianjin Ruiwang New Material Technology Co
Published 12 Nov 2026. 41-page investigative report on who is behind Tianjin Ruiwang New Material Technology Co: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.
Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.
Executive summary
Across 185 Finnrick lab tests, Tianjin Ruiwang shows a 64% overall pass rate, with the supplied record reporting 119 pass / 65 fail. The record is sharply product-specific rather than brand-wide: GHK-Cu is the strongest documented line, Retatrutide and Tirzepatide are the more defensible high-volume choices, and TB-500 sits in the fail-heavy tail. The report also shows where those rankings compress under stricter grading.
The corporate trail is messier than the vendor name suggests. A UK company is active but dormant; the closest name-matched Chinese company has named shareholders and then a 2026 cancellation by resolution to dissolve. Public records do not identify the current legal seller, payment beneficiary or shipping entity that should stand behind a peptide order.
Operationally, the visible footprint looks more like an industrial-chemical and export-trading network that added peptide sales through social and platform channels. Public sources reviewed did not identify a peptide manufacturing site, upstream supplier, QA/QC lead, analytical-review authority or batch-release signatory; that is a disclosure gap, not proof no competent personnel exist.
The buyer-facing controls are the main non-lab problem. Both tianjinruiwang.com and tjruiwang.com were unregistered or NXDOMAIN in the capture, multiple WhatsApp and social contacts circulate, and the reviewed COA evidence includes an unbatched Ascend/Janoshik-linked lead plus promotional material recorded as Batch Unknown. Buyers considering this source need vial-matching batch evidence, not a brand-name assumption.
Inside the full report:
- Per-product pass/fail rates and methodology-divergence charts for all 12 tested products
- Companies House filings and QCC Chinese corporate records, including ownership, dormancy and cancellation evidence
- Domain, DNS, WHOIS/RDAP and channel-authentication analysis for Tianjin Ruiwang web and WhatsApp routes
- COA and batch-traceability review, including the unbatched Ascend/Janoshik-linked lead and Batch Unknown promotional material
- Sales-network and personnel footprint across Made-in-China, Bline, Facebook, LinkedIn and Instagram
- Related-entity watch items separating Wu-linked companies, Zhongbiao and Hunan Ruiwang from proven Ruiwang control
Risk assessment
- Product-specific quality inconsistency risk — high: Weakest documented products are NAD+ 21.2%, TB-500 28.17%, Tesamorelin 41.24% and BPC-157 48.94%; GHK-Cu 85.36%, Retatrutide 77.41% and Tirzepatide 73.84% are stronger but still batch-dependent.
- Legal-seller continuity risk — high: The Chinese entity was cancelled on 2026-02-26, the UK company is dormant, and no public record identifies the current contracting/payment/shipping entity.
- Traceability / vial-to-COA linkage risk — high: No public batch lookup, signed COA endpoint or vial-matching COA system was found; field leads include an unbatched COA submission and Batch Unknown promotional material.
- Official-channel and brand-authentication risk — high: tianjinruiwang.com and tjruiwang.com were unregistered/NXDOMAIN, multiple WhatsApp/social contacts circulate, and the vendor provides no authoritative channel list or anti-counterfeit path.
- Manufacturer-verification / upstream-supplier transparency risk — high: Public records point to industrial trading and do not identify an owned peptide synthesis site, GMP facility, upstream supplier or peptide QC laboratory.
- Technical accountability risk — medium: No public QA/QC lead, analytical-review authority, batch-release signatory or peptide technical manager was identified; this is a public-record gap, not proof none exists.